Abionic

company

About

Abionic is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology.

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
Fr20M
Industries
Biotechnology,Health Care,Life Science,Medical,Nanotechnology,Pharmaceutical
Founded date
Jan 1, 2010
Number Of Employee
51 - 100
Operating Status
Active

Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.

Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.

Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.

Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.

Abionic appreciates the support it has received from:

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
Fr25.80M
Abionic has raised a total of Fr25.80M in funding over 2 rounds. Their latest funding was raised on Mar 28, 2018 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 28, 2018 Series C Fr20M 1 Detail
Oct 14, 2014 Series B Fr3.80M 1 MedHoldings Detail
Apr 26, 2012 Series A Fr2M 1 MedHoldings Detail

Investors

Number of Lead Investors
Number of Investors
2
2
Abionic is funded by 2 investors. MedHoldings and Verve Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
MedHoldings Yes Series B
Verve Ventures Series C